Basic Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 14, 2023; 29(14): 2134-2152
Published online Apr 14, 2023. doi: 10.3748/wjg.v29.i14.2134
Anti-inflammatory effect and antihepatoma mechanism of carrimycin
Xiu-Yan Li, Yu-Ting Luo, Yan-Hong Wang, Zhi-Xin Yang, Yu-Zhou Shang, Qing-Xia Guan
Xiu-Yan Li, Yu-Ting Luo, Yan-Hong Wang, Zhi-Xin Yang, Yu-Zhou Shang, Qing-Xia Guan, Key Laboratory of Basic and Application Research of Beiyao, Heilongjiang University of Chinese Medicine, Harbin 150040, Heilongjiang Province, China
Author contributions: Li XY, Luo YT, Guan QX, Wang YH, Yang ZX, and Shang YZ performed the experiments and acquired and analyzed the data; Li XY and Luo YT wrote the manuscript; and all authors approved the final version of the article.
Supported by Heilongjiang Natural Science Foundation, No. LH2022H085 and H2016057; and Scientific Research Project of Heilongjiang Health Committee, No. 2020-293.
Institutional animal care and use committee statement: All animal experiments conformed to the internationally accepted principles for the care and use of laboratory animals (Scientific Research Project of Heilongjiang Health Committee, No. 2020-293).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qing-Xia Guan, PhD, Teacher, Key Laboratory of Basic and Application Research of Beiyao, Heilongjiang University of Chinese Medicine, No. 24 Heping Road, Xiangfang District, Harbin 150040, Heilongjiang Province, China. 546105832@qq.com
Received: November 28, 2022
Peer-review started: November 28, 2022
First decision: December 20, 2022
Revised: December 29, 2022
Accepted: March 9, 2023
Article in press: March 9, 2023
Published online: April 14, 2023
Processing time: 135 Days and 20.5 Hours
ARTICLE HIGHLIGHTS
Research background

As a new national first-class drug, carrimycin (CAM) has much potential medicinal value. The clinical results show that its antibacterial activity and pharmacodynamic activity are significantly greater than those of similar antibiotics. Through the combination of animal experiments and network pharmacology, this study demonstrates that CAM plays a positive role in the treatment of inflammation and some cancers.

Research motivation

At present, the mechanism of CAM in the treatment of liver cancer is not clear, so the mechanism can be speculated by network pharmacology.

Research objectives

To gain a deeper understanding of CAM, the distribution, metabolism and anti-inflammatory effects of CAM in organs were assessed, and the anti-liver cancer mechanism of CAM was analyzed.

Research methods

Taking the content of isovaleryl spiramycin III as the index, the distribution and metabolism of CAM in various tissues and organs of mice and its effect on inflammatory factors in various tissues and organs of mice were detected. The target of CAM was determined by reverse molecular docking technology, the disease type corresponding to each target protein was selected, the target protein disease type network was established, and the key targets of CAM in liver cancer were screened by network pharmacological methods. The core target was verified by molecular docking and visual analysis.

Research results

The maximum CAM concentration was reached in the liver, kidney, lung and spleen 2.5 h after intragastric administration. In the intestine, the maximum drug concentration was reached 0.5 h after administration. CAM is predicted to regulate related pathways by acting on many targets, such as albumin, estrogen receptor 1, epidermal growth factor receptor and caspase 3, to treat cancer, inflammation and other diseases.

Research conclusions

CAM had an inhibitory effect on inflammation. It also predicts the multitarget, complexity of CAM involving multiple pathways and the diversity of CAM effects in the treatment of liver cancer, which provides a basis and direction for further clinical research.

Research perspectives

We examined the distribution and metabolism of CAM in murine tissues and organs and the effect of CAM on inflammatory factors and performed a systematic analysis of the targets and biological pathways involved in the treatment of liver cancer with CAM by network pharmacology, which led to further insights into the mechanism of treatment of the disease with CAM.